GlassScriptPhysician profile
Robert Milton Clark
NPI 1386675890
$8,637.31
in general payments reported to CMS, 2019-2025
64 companies · $1,207 in 2025
The $1,207 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $850 · 2020: $683 · 2021: $1,119 · 2022: $1,437 · 2023: $1,588 · 2024: $1,754 · 2025: $1,207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,548.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,308.41 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $779.45 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $638.51 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $543.95 | 2019-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $500.29 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $486.98 | 2021-2025 | Rexulti |
| Abbott Laboratories | $414.92 | 2021-2025 | Freestyle Libre 3, Mitraclip |
| Pfizer INC. | $352.79 | 2019-2024 | |
| Dexcom, INC. | $305.99 | 2023-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $290.30 | 2019-2025 | Xifaxan, Trulance |
| Amgen INC. | $265.96 | 2019-2025 | Repatha, Otezla, Otezla |
| Inspire Medical Systems, INC. | $215.79 | 2022-2023 | Inspire |
| Amarin Pharma, INC. | $183.95 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.80 | 2019-2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $182.21 | 2021-2025 |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.